Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

Authors:

Abstract
Background. Drug concentration monitoring may be useful to guide therapeutic adjustments for anti–tumor necrosis factor agents in Crohn's disease. The relation

This publication has 25 references indexed in Scilit: